MapLight Therapeutics, Inc.
MPLT$770M
Small CapNASDAQBiotechnology🇺🇸North America114 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
4
Next Catalyst
Aug 15, 2026
22wMarket Overview
Stock performance and key metrics
MPLT News
Catalyst Timeline
4 upcoming, 0 past
Drug Pipeline
ML-007C-MA
Psychosis Associated With Alzheimer's Disease
ML-004 (IR)/(ER) tablet
Autism Spectrum Disorder
ML-007C-MA BID
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ML-007C-MA | Phase 2 | Psychosis Associated With Alzheimer's Disease | - | - |
ML-004 (IR)/(ER) tablet | Phase 2 | Autism Spectrum Disorder | - | - |
ML-007C-MA BID | Phase 2 | Schizophrenia | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply